Professors Yoo Tae-ryong, Park Yong-soo, and Kim Young-kwang of the Catholic Medical University selected the 'Global Medical Scientist Training Project'
Jul 07, 2024
Professor Yoo Tae-ryong and Park Yong-soo of the Catholic University School of Medicine's Anatomy Class and Professor Kim Young-kwang of the Pathology Class were selected for the '2024 Global Doctor Scientist Training Project' supported by the Ministry of Health and Welfare and organized by the Korea Health Industry Promotion Agency.
The Global Medical Scientist Training Project is a project to support young medical scientists who conduct new technology convergence research based on clinical knowledge to foster convergent global innovative talents and establish a stable research foundation linked to health care field demand.
Professor Yoo Tae-ryong plans to conduct a study to verify the effectiveness of Bag3-inflammasome as a new treatment by identifying the neuroinflammatory and endoplasmic reticulum stress control mechanisms after stroke. Currently, there is almost no treatment for neurological damage to stroke, and this study is expected to discover new treatment targets in the brain stem that control neuroinflammation and secure major source technologies.
Professor Park Yong-soo intends to develop artificial visual technology for patients with visual impairment due to macular degeneration. The goal of the research is to create a cell membrane current by complex thermoelectric stimulation in cells treated with gold nanoparticles to implement artificial visual technology suitable for living organisms and safe. This technology can also be applied universally to nerve cells acting on the same principle to expand into artificial neural excitation technology to restore the function of degenerative neurological diseases.
Professor Kim Young-kwang plans to establish a screening system to explore resistance mutations of anticancer drugs used in patients with EGFR (receptor binding to epithelial cell growth factors that promote epithelial cell growth and differentiation), which accounts for 34% of non-cellular lung cancers. Using next-generation gene editing technology, it aims to create a library that assigns all possible mutations to the core region of the EGFR gene to discover resistant mutations that may occur after administration of anticancer drugs with high accuracy.
Professor Yoo Tae-ryong "We intend to conduct a multidisciplinary analysis encompassing transcriptomic histological and neurobehavioral examination of animal models and patient samples to present a new paradigm for intractable neurological disease research and lay the groundwork for the development of treatments that can alleviate patient pain."
Professor Park Yong-soo said, "The development of technology for overcoming visual impairment is a technology that is drawing attention to the extent that clinical trials are already underway overseas. Through this study, we want to develop the original technology for overcoming visual impairment and create a foundation for continuous research to achieve results that are helpful to patients." he said.
Professor Kim Young-kwang said "Mutant screening methods using gene editing technology are expected to help set up treatments in clinical practice through comprehensive exploration of resistant mutations, and will be able to lay the technical foundation for exploring resistant mutations for other anticancer drugs in the future."
Meanwhile, the selected research project will run for two years and nine months, with professors Yoo Tae-ryong and Kim Young-kwang receiving 550 million won and Park Yong-soo 535 million won from the government.
The Global Medical Scientist Training Project is a project to support young medical scientists who conduct new technology convergence research based on clinical knowledge to foster convergent global innovative talents and establish a stable research foundation linked to health care field demand.
Professor Yoo Tae-ryong plans to conduct a study to verify the effectiveness of Bag3-inflammasome as a new treatment by identifying the neuroinflammatory and endoplasmic reticulum stress control mechanisms after stroke. Currently, there is almost no treatment for neurological damage to stroke, and this study is expected to discover new treatment targets in the brain stem that control neuroinflammation and secure major source technologies.
Professor Park Yong-soo intends to develop artificial visual technology for patients with visual impairment due to macular degeneration. The goal of the research is to create a cell membrane current by complex thermoelectric stimulation in cells treated with gold nanoparticles to implement artificial visual technology suitable for living organisms and safe. This technology can also be applied universally to nerve cells acting on the same principle to expand into artificial neural excitation technology to restore the function of degenerative neurological diseases.
Professor Kim Young-kwang plans to establish a screening system to explore resistance mutations of anticancer drugs used in patients with EGFR (receptor binding to epithelial cell growth factors that promote epithelial cell growth and differentiation), which accounts for 34% of non-cellular lung cancers. Using next-generation gene editing technology, it aims to create a library that assigns all possible mutations to the core region of the EGFR gene to discover resistant mutations that may occur after administration of anticancer drugs with high accuracy.
Professor Yoo Tae-ryong "We intend to conduct a multidisciplinary analysis encompassing transcriptomic histological and neurobehavioral examination of animal models and patient samples to present a new paradigm for intractable neurological disease research and lay the groundwork for the development of treatments that can alleviate patient pain."
Professor Park Yong-soo said, "The development of technology for overcoming visual impairment is a technology that is drawing attention to the extent that clinical trials are already underway overseas. Through this study, we want to develop the original technology for overcoming visual impairment and create a foundation for continuous research to achieve results that are helpful to patients." he said.
Professor Kim Young-kwang said "Mutant screening methods using gene editing technology are expected to help set up treatments in clinical practice through comprehensive exploration of resistant mutations, and will be able to lay the technical foundation for exploring resistant mutations for other anticancer drugs in the future."
Meanwhile, the selected research project will run for two years and nine months, with professors Yoo Tae-ryong and Kim Young-kwang receiving 550 million won and Park Yong-soo 535 million won from the government.
|
bellho@sportschosun.com
